All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Sacituzumab Tirumotecan Plus Pembrolizumab Is Set to Be Evaluated in TNBC

October 6th 2025

Sacituzumab tirumotecan plus pembrolizumab is currently being evaluated for select patients with TNBC in the phase 3 TroFuse-012 trial.

Atebimetinib Plus Chemo Makes Case As Potential Frontline Option in Pancreatic Cancer

October 6th 2025

Martin F. Dietrich, MD, PhD, discusses the potential role of atebimetinib plus chemotherapy in frontline pancreatic cancer.

Older Cancer Clinical Trials May Continue to Offer Relevant Lessons Learned

October 5th 2025

Maurie Markman, MD, details the lessons learned following results from older clinical trials within the oncology space.

Five Under 5: Top Oncology Videos for the Week of 9/28

October 5th 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, and prostate cancer, myelofibrosis.

The OncFive: Top Oncology Articles for the Week of 9/28

October 4th 2025

The FDA clears maintenance lurbinectedin combination in lung cancer, T-DxD sBLA in HER2-positive breast cancer is accepted for review, and more.

Case Study Showcases Potential Role of Targeted Therapy for Secondary T-Cell Lymphoma After CAR T-Cell Therapy

October 4th 2025

A mogamulizumab-based combination led to complete remission in a patient with CAR-positive T-cell lymphoma with CCR4 overexpression.

Q4 2025: 10 FDA Decisions to Watch in the Realm of Oncology

October 3rd 2025

Here is your Q4 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for belantamab mafodotin, revumenib, sevabertinib, and more.

OncLive Poll Results Spotlight Highly Anticipated Hematology Topics Ahead of ESMO 2025

October 3rd 2025

Multiple myeloma and non-Hodgkin lymphoma emerge as key hematology topics ahead of ESMO 2025, followed by MPNs and T-cell lymphoma.

OncLive Polls Highlight Top Votes on Anticipated Breast Cancer Abstracts at ESMO 2025

October 3rd 2025

Breast cancer experts vote on their most anticipated abstracts on social media ahead of the 2025 ESMO Congress.

Mayo Clinic Research Improves Dense Breast Cancer Screening and Early Detection

October 3rd 2025

The addition of molecular breast imaging to a 3D mammogram more than doubled the ability to find cancer in dense tissue, according to Mayo Clinic investigators.

JNJ-190 Plus Anti–PD-1 Immune Checkpoint Inhibitors Generate Early Antitumor Activity in HNSCC

October 3rd 2025

Early objective responses have been shown with JNJ-1900 plus immune checkpoint inhibitors for recurrent/metastatic HNSCC.

Case Study Highlights Tumor Burden Reduction With Paxalisib Combo in Metastatic TNBC

October 3rd 2025

Paxalisib plus pembrolizumab and chemotherapy led to an 86% reduction in tumor burden in a patient with metastatic triple-negative breast cancer.

Real-World Study Demonstrates Safety and Efficacy of Avelumab/Axitinib in Advanced RCC

October 3rd 2025

A real-world analysis shows avelumab plus axitinib is safe and effective in advanced RCC.

GPC3 Offers Highly Specific Target in HCC

October 3rd 2025

GPC3 has the potential to be targeted in patients with HCC with reduced off-target toxicities compared with other targeted agents.

OncLive’s September Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

October 3rd 2025

Here is your guide to all therapeutic options that were approved by the FDA in September 2025 spanning tumor types.

FDA Approves Lurbinectedin Plus Atezolizumab as First-Line Maintenance Therapy for ES-SCLC

October 2nd 2025

The FDA approved lurbinectedin plus atezolizumab as first-line maintenance for ES-SCLC that has not progressed after frontline induction therapy.

Experts Reflect on Ideas From MiBA 2025 That Will Propel the Future of AI-Driven Oncology

October 2nd 2025

Oncology experts and AI advocates discuss insights about how AI can help manage tasks, keep up with evolving treatment practices, and improve patient care.

OncLive’s September EMA Regulatory Recap: Key EU Approvals in Oncology

October 2nd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in September 2025.

New Diagnostic Tool Developed at Dana-Farber Revolutionizes Acute Leukemia Diagnosis

October 2nd 2025

Five new faculty members have joined the Roswell Park Care Network, with St. Joseph’s Health in Syracuse to begin thoracic surgery services.

Pembrolizumab Plus Chemotherapy Shows Preliminary Activity in Advanced Penile Cancer

October 2nd 2025

The addition of the PD-1 inhibitor to platinum-based chemotherapy demonstrated proof of concept for the use of chemoimmunotherapy in patients with PSCC.